: Phathom’s stock falls after receiving FDA letters


Shares of Phathom Pharmaceuticals Inc. PHAT, -29.67% tumbled about 23% in premarket trading on Friday, the day after the company said it received complete response letters from the Food and Drug Administration related to vonoprazan, which is approved for two indications and had also been submitted to the regulator as a potential treatment for erosive esophagitis. Phathom said it plans to meet with the FDA in the first quarter of this year to discuss resubmitting vonoprazan. The company’s stock is down 38.4% over the past year, while the broader S&P 500 SPX, +0.22% has declined 9.5%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Moneyist: ‘I felt hoodwinked’: My contractor charged me $3,000 for a new door after quoting me $2,000, so I canceled the job and check. Should I pay his $30 returned-check fee?
Next article: Are you worse off than you were a year ago? Half of Americans say yes — the most since the Great Recession.


Please enter your comment!
Please enter your name here